We, from Cristália Lab, assume our social role by developing a positive relationship with the communities where we are inserted and with the environment, believing that, through our actions we can contribute to a better world.
Social Responsibility and Sustainability are being practised by the development of programs to live up to our standpoints.
Every year, several educational activities are developed, such as educational projects for children, donation of medicine to health programs, and a contribution that provides educational materials and resources to a large number of institutions which offer aid and assistance to poor communities.
For many years, our commitment towards the environment has included goals and plans to properly manage residues of our processes. It's important to point out that all residues produced in our manufacturing units are burned and destroyed by specialized companies, in accordance to the local legislation.
The creation of about 8,000 direct and indirect jobs and the offering to the market limited prices on high quality drugs, which allows the treatment to a great number of Brazilian citizens, reflect our social contribution. We also emphasize the work of Brazilian scientists of a large number of universities within the country.
As a result of our performance, we generate job opportunities and development for Brazilian scientists, producing alternatives to create medicines at low cost - which contribute to the optimization of resources of the governmental programs, increasing the access to health solutions for a larger group of people in need.
“To produce the highest quantity of medications as possible with quality and fair price, stimulate national research; continuously seek for innovation, in order to contribute solving health problems.”
A HISTORY FOCUSED ON INNOVATION – Cristália is always a step ahead.
Cristália Lab, founded in 1972, has focused on serving Brazilian hospitals. Initially, under specialties such as Psychiatry; later on, in fields such as Anesthesia and Algology, sectors in which the company became leader in Latin America.
With a highly creative and innovative positioning, Cristália implemented its Research, Development and Innovation Center, with excellence, being ranked on top of its industry for solving problems, in all medical areas.
The establishment of partnerships among national and international associations led Cristália to have an unique and large development. These improvements, local and general, allowed us to have new anesthetics, more efficient and safer, many of which are under patents in Brazil, United States, European Union and China.
By providing a high level of RD&I we have been selected to offer “reference standards” to the United States Pharmacopeia. An honor for our company. Also, we have been appointed in 2007, by Finep (a top Brazilian Research Institute) as the most innovative pharmaceutical industry in our country.
Today we cover the entire Brazilian territory and our exports reach about 40 countries in Latin America, Middle East, Asia and Africa.
Again, we’ve demonstrated being a company with differentiation, with a high level of competence – by developing the first pharmaceutical product obtained by vertical synthesis in Brazil, from its conception to its clinical tests and aimed to the Erectile Dysfunction treatment.
Innovation has always been among us for the past decades, representing our efforts on planning, strategic decisions and investments during the past decades. This way, Cristália Lab has become a reference in the country in the field of research and development of new substances.
By sharing our vision with the most renowned national scientists from the best Brazilian universities, our Research, Development and Innovation (RD&I) Center, has made Cristália responsible for the development of:
Five substances synthesized by our Active Pharmaceutical Ingredients (API) Manufacturing Unity were considered as “reference standards” by the United States Pharmacopeia (USP), an American agency of worldwide influence, providing quality standards for the production of pharmaceutical products.
This means that, both the United States and other 36 countries, have adopted this Pharmacopeia as reference, using these substances synthesized by Cristália Lab as primary standard, to check the quality of the active ingredients manufactured or used in the production of their medicines.